Your request to link to rcsb for p110?/p85?

• 1FU5: nmr structure of the n-sh2 domain of the p85 subunit of pi3- kinase complexed to a doubly phosphorylated peptide derived from polyomavirus middle t antigen (10.1021/BI001474D )
• 1FU6: nmr structure of the n-sh2 domain of the p85 subunit of pi3- kinase (10.1021/BI001474D )
• 1H9O: phosphatidylinositol 3-kinase, p85-alpha subunit: c-terminal sh2 domain complexed with a tyr751 phosphopeptide from the pdgf receptor, crystal structure at 1.79 a (10.1107/S0907444901012434 )
• 1OO3: p395s mutant of the p85 regulatory subunit of the n- terminal src homology 2 domain of pi3-kinase (10.1021/BI034353X )
• 1OO4: p395s mutant of the p85 regulatory subunit of the n- terminal src homology 2 domain of pi3-kinase complexed to a peptide derived from pdgfr (10.1021/BI034353X )
• 1PBW: structure of bcr-homology (bh) domain (10.1073/PNAS.93.25.14373 )
• 1PHT: phosphatidylinositol 3-kinase p85-alpha subunit sh3 domain, residues 1-85 (10.1006/JMBI.1996.0190 )
• 1PIC: phosphatidylinositol 3-kinase, p85-alpha subunit: c- terminal sh2 domain complexed with a tyr751 phosphopeptide from the pdgf receptor, nmr, minimized mean structure
• 1PKS: structure of the pi3k sh3 domain and analysis of the sh3 family (10.1016/0092-8674(93)90582-B )
• 1PKT: structure of the pi3k sh3 domain and analysis of the sh3 family (10.1016/0092-8674(93)90582-B )
• 1PNJ: solution structure and ligand-binding site of the sh3 domain of the p85alpha subunit of phosphatidylinositol 3-kinase (10.1016/0092-8674(93)90259-S )
• 1QAD: crystal structure of the c-terminal sh2 domain of the p85 alpha regulatory subunit of phosphoinositide 3-kinase: an sh2 domain mimicking its own substrate 26-sep-01 1qad 3 atom title (10.1006/JMBI.1999.3111 )
• 2ENQ: solution structure of the c2 domain from human pi3-kinase p110 subunit alpha
• 2IUG: crystal structure of the pi3-kinase p85 n-terminal sh2 domain (10.1038/NSB0496-364 )
• 2IUH: crystal structure of the pi3-kinase p85 n-terminal sh2 domain in complex with c-kit phosphotyrosyl peptide (10.1038/NSB0496-364 )
• 2IUI: crystal structure of the pi3-kinase p85 n-terminal sh2 domain in complex with pdgfr phosphotyrosyl peptide (10.1038/NSB0496-364 )
• 2PNA: structure of an sh2 domain of the p85 alpha subunit of phosphatidylinositol-3-oh kinase (10.1038/358684A0 )
• 2PNB: structure of an sh2 domain of the p85 alpha subunit of phosphatidylinositol-3-oh kinase (10.1038/358684A0 )
• 2PNI: solution structure and ligand-binding site of the sh3 domain of the p85alpha subunit of phosphatidylinositol 3-kinase (10.1016/0092-8674(93)90259-S )
• 2RD0: structure of a human p110alpha/p85alpha complex (10.1126/SCIENCE.1150799 )
• 2V1Y: structure of a phosphoinositide 3-kinase alpha adaptor- binding domain (abd) in a complex with the ish2 domain from p85 alpha (10.1126/SCIENCE.1135394 )
• 3HHM: crystal structure of p110alpha h1047r mutant in complex with nish2 of p85alpha and the drug wortmannin (10.1073/PNAS.0908444106 )
• 3HIZ: crystal structure of p110alpha h1047r mutant in complex with nish2 of p85alpha (10.1073/PNAS.0908444106 )
• 3I5R: pi3k sh3 domain in complex with a peptide ligand (10.1515/BC.2010.003 )
• 3I5S: crystal structure of pi3k sh3 (10.1515/BC.2010.003 )
• 3ZIM: discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase pi3kalpha (10.1021/JM3008745 )
• 4A55: crystal structure of p110alpha in complex with ish2 of p85alpha and the inhibitor pik-108 (10.1038/ONC.2011.532 )
• 4JPS: co-crystal structures of the lipid kinase pi3k alpha with pan and isoform selective inhibitors (10.1016/J.BMCL.2013.05.007 )
• 4L1B: crystal structure of p110alpha complexed with nish2 of p85alpha (10.1021/ML400378E )
• 4L23: crystal structure of p110alpha complexed with nish2 of p85alpha and pi-103 (10.1021/ML400378E )
• 4L2Y: crystal structure of p110alpha complexed with nish2 of p85alpha and compound 9d (10.1021/ML400378E )
• 4OVU: crystal structure of p110alpha in complex with nish2 of p85alpha
• 4OVV: crystal structure of pi3kalpha in complex with dic4-pip2 10-sep-14 4ovv 1 title
• 4TUU: isolated p110a subunit of pi3ka provides a platform for structure- based drug design (10.1002/PRO.2517 )
• 4TV3: isolated p110a subunit of pi3ka provides a platform for structure- based drug design (10.1002/PRO.2517 )
• 4WAF: crystal structure of a novel tetrahydropyrazolo[1,5-a]pyrazine in an engineered pi3k alpha (10.1021/ML500353P )
• 4YKN: pi3k alpha lipid kinase with active site inhibitor (10.1021/ACSMEDCHEMLETT.5B00025 )
• 4ZOP: co-crystal structure of lipid kinase pi3k alpha with a selective phosphatidylinositol-3 kinase alpha inhibitor
• 5AUL: pi3k p85 c-terminal sh2 domain/cd28-derived peptide complex (10.1074/JBC.M116.755173 )
• 5DXH: p110alpha/p85alpha with compound 5 (10.1021/ACS.JMEDCHEM.5B01483 )
• 5DXT: p110alpha with gdc-0326 (10.1021/ACS.JMEDCHEM.5B01483 )
• 5DXU: p110delta/p85alpha with gdc-0326 (10.1021/ACS.JMEDCHEM.5B01483 )
• 5FI4: discovery of imidazo[1,2-a]-pyridine inhibitors of pan-pi3 kinases that are efficacious in a mouse xenograft model (10.1016/J.BMCL.2016.01.003 )
• 5GJI: pi3k p85 n-terminal sh2 domain/cd28-derived peptide complex (10.1074/JBC.M116.755173 )
• 5ITD: crystal structure of pi3k alpha with pi3k delta inhibitor (10.1021/ACSMEDCHEMLETT.6B00119 )
• 5M6U: human pi3kdelta in complex with lasw1579 (10.1021/ACSMEDCHEMLETT.6B00438 )
• 5SW8: crystal structure of pi3kalpha in complex with fragments 7 and 11 (10.1016/J.BMC.2017.01.012 )
• 5SWG: crystal structure of pi3kalpha in complex with fragments 5 and 21 (10.1016/J.BMC.2017.01.012 )
• 5SWO: crystal structure of pi3kalpha in complex with fragments 4 and 19 (10.1016/J.BMC.2017.01.012 )
• 5SWP: crystal structure of pi3kalpha in complex with fragments 6 and 24 (10.1016/J.BMC.2017.01.012 )
• 5SWR: crystal structure of pi3kalpha in complex with fragments 20 and 26 (10.1016/J.BMC.2017.01.012 )
• 5SWT: crystal structure of pi3kalpha in complex with fragments 17 and 27 (10.1016/J.BMC.2017.01.012 )
• 5SX8: crystal structure of pi3kalpha in complex with fragments 12 and 15 (10.1016/J.BMC.2017.01.012 )
• 5SX9: crystal structure of pi3kalpha in complex with fragment 14 (10.1016/J.BMC.2017.01.012 )
• 5SXA: crystal structure of pi3kalpha in complex with fragment 10 (10.1016/J.BMC.2017.01.012 )
• 5SXB: crystal structure of pi3kalpha in complex with fragment 23 (10.1016/J.BMC.2017.01.012 )
• 5SXC: crystal structure of pi3kalpha in complex with fragment 8 (10.1016/J.BMC.2017.01.012 )
• 5SXD: crystal structure of pi3kalpha in complex with fragment 22 (10.1016/J.BMC.2017.01.012 )
• 5SXE: crystal structure of pi3kalpha in complex with fragments 19 and 28 (10.1016/J.BMC.2017.01.012 )
• 5SXF: crystal structure of pi3kalpha in complex with fragment 9 (10.1016/J.BMC.2017.01.012 )
• 5SXI: crystal structure of pi3kalpha in complex with fragment 13 (10.1016/J.BMC.2017.01.012 )
• 5SXJ: crystal structure of pi3kalpha in complex with fragment 29 (10.1016/J.BMC.2017.01.012 )
• 5SXK: crystal structure of pi3kalpha in complex with fragment 18 (10.1016/J.BMC.2017.01.012 )
• 5T8F: p110delta/p85alpha with taselisib (gdc-0032) (10.1021/ACS.JMEDCHEM.6B01363 )
• 5UBR: crystal structure of pi3k alpha in complex with a 7-(3-(piperazin-1- yl)phenyl)pyrrolo[2,1-f][1,2,4] triazin-4-amine deriviatine (10.1016/J.BMCL.2017.01.016 )
• 5UBT: crystal structure of pi3k delta in complex with a 7-(3-(piperazin-1- yl)phenyl)pyrrolo[2,1-f][1,2,4] triazin-4-amine deriviatine (10.1016/J.BMCL.2017.01.016 )
• 5UK8: the co-structure of (r)-4-(6-(1-(cyclopropylsulfonyl)cyclopropyl)-2- (1h-indol-4-yl)pyrimidin-4-yl)-3-methylmorpholine and a rationally designed pi3k-alpha mutant that mimics atr (10.1016/J.JMB.2017.04.006 )
• 5UKJ: the co-structure of n,n-dimethyl-4-[(6r)-6-methyl-5-(1h-pyrrolo[2,3- b]pyridin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5- a]pyrazin-3- yl]benzenesulfonamide and a rationally designed pi3k-alpha mutant that mimics atr (10.1016/J.JMB.2017.04.006 )
• 5UL1: the co-structure of 3-amino-6-(4-((1-(dimethylamino)propan-2-yl) sulfonyl)phenyl)-n-phenylpyrazine-2-carboxamide and a rationally designed pi3k-alpha mutant that mimics atr (10.1016/J.JMB.2017.04.006 )
• 5VLR: crystal structure of pi3k delta in complex with a trifluoro-ethyl- pyrazol-pyrolotriazine inhibitor (10.1021/ACS.JMEDCHEM.7B00618 )
• 5XGH: crystal structure of pi3k complex with an inhibitor (10.1038/S41598-017-15260-5 )
• 5XGI: crystal structure of pi3k complex with an inhibitor
• 5XGJ: crystal structure of pi3k complex with an inhibitor
• 6D81: structure of the bovine p85a bh domain (10.1038/S41598-018-25487-5 )
• 6D82: structure of the bovine p85a bh domain (10.1038/S41598-018-25487-5 )
• 6D85: structure of the bovine p85a bh domain e217k mutant (10.1038/S41598-018-25487-5 )
• 6D86: structure of the bovine p85a bh domain (10.1038/S41598-018-25487-5 )
• 6D87: structure of the bovine p85alpha bh domain, r262t mutant (10.1038/S41598-018-25487-5 )
• 6G6W: human pi3kdelta in complex with ligand lasw1976 (10.1021/ACS.JMEDCHEM.8B00873 )
• 6GVF: crystal structure of pi3k alpha in complex with 3-(2-amino- benzooxazol-5-yl)-1-isopropyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine (10.1021/ACSMEDCHEMLETT.9B00401 )
• 6GVG: crystal structure of pi3k alpha in complex with 3-(2-amino- benzooxazol-5-yl)-1-isopropyl-4-methyl-1h-pyrazolo[3,4-d]pyrimidin-6- ylamine (10.1021/ACSMEDCHEMLETT.9B00401 )
• 6GVH: crystal structure of pi3k alpha in complex with 3-(2-amino- benzooxazol-5-yl)-4-chloro-1-isopropyl-1h-pyrazolo[3,4-d]pyrimidin-6- ylamine (10.1021/ACSMEDCHEMLETT.9B00401 )
• 6GVI: crystal structure of pi3k alpha in complex with 3-(2-amino- benzooxazol-5-yl)-1-isopropyl-1h-pyrazolo[3,4-d]pyrimidine-4,6- diamine (10.1021/ACSMEDCHEMLETT.9B00401 )
• 6MRP: structure of the bovine p85a bh domain r228e mutant (10.18632/ONCOTARGET.26432 )
• 6NCT: structure of p110alpha/nish2 - vector data collection (10.3390/MOLECULES24030496 )
• 6OAC: pqr530 [(s)-4-(difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino- 1,3,5-triazin-2-yl)pyridin-2-amine] bound to the pi3ka catalytic subunit p110alpha (10.1021/ACS.JMEDCHEM.9B00525 )
• 6OCO: human pi3kdelta in complex with compound 6 (10.1016/J.BMCL.2019.126715 )
• 6OCU: human pi3kdelta in complex with compound 29 (10.1016/J.BMCL.2019.126715 )
• 6PYR: human pi3kdelta in complex with compound 2-10 ((3s)-3-benzyl-3-methyl- 5-[5-(2-methylpyrimidin-5-yl)pyrazolo[1,5-a]pyrimidin-3-yl]-1,3- dihydro-2h-indol-2-one) (10.1016/J.BMCL.2019.08.004 )
• 6PYS: human pi3kalpha in complex with compound 2-10 ((3s)-3-benzyl-3-methyl- 5-[5-(2-methylpyrimidin-5-yl)pyrazolo[1,5-a]pyrimidin-3-yl]-1,3- dihydro-2h-indol-2-one) (10.1016/J.BMCL.2019.08.004 )
• 6PYU: human pi3kdelta in complex with compound 4-2 ((3s)-1'- (cyclopropanecarbonyl)-5-(quinoxalin-6-yl)spiro[indole-3,2'- pyrrolidin]-2(1h)-one) (10.1016/J.BMCL.2019.08.004 )
• 6R4R: cryo-em structure of the pi3-kinase sh3 domain amyloid fibril (10.1038/S41467-019-11320-8 )
• 6VO7: crystal structure of pi3k-alpha ras binding domain (rbd) (10.1016/J.JMB.2021.166838 )
• 7CIO: molecular interactions of cytoplasmic region of ctla-4 with sh2 domains of pi3-kinase (10.1016/J.MOLIMM.2020.12.002 )
• 7JIS: human pi3kdelta in complex with compound 2f (10.1021/ACSMEDCHEMLETT.0C00441 )
• 7JIU: human pi3kdelta in complex with compound 2f (10.1021/ACSMEDCHEMLETT.0C00441 )
• 7K6M: crystal structure of pi3kalpha selective inhibitor pf-06843195 (10.1021/ACS.JMEDCHEM.0C01652 )
• 7K6N: crystal structure of pi3kalpha selective inhibitor 11-1575 (10.1021/ACS.JMEDCHEM.0C01652 )
• 7K6O: crystal structure of pi3kalpha inhibitor 10-5429 (10.1021/ACS.JMEDCHEM.0C01652 )
• 7K71: crystal structure of pi3kalpha inhibitor 4-0686 (10.1021/ACS.JMEDCHEM.0C01652 )
• 7LM2: human pi3kdelta in complex with compound 3c (10.1021/ACS.JMEDCHEM.1C00237 )